Drug Profile
PRO 01
Alternative Names: PRO-01Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator Prothix
- Class Monoclonal antibodies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Thromboembolism
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for preclinical development in Thromboembolism in Netherlands
- 20 Jul 2016 PRO 01 is available for licensing - http://prothix.com/strategy/
- 20 Jul 2016 Preclinical trials in Thromboembolism in Netherlands (unspecified route)